Last reviewed · How we verify
NCT04943419
Myeloid-derived Suppressor Cells in Colorectal Cancer
trial testing Level of Myeloid-Derived Suppressor Cells in Colorectal Cancer in 90 participants. Completed in 21 June 2021.
27 February 2021
Quick facts
| Lead sponsor | Jagiellonian University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 April 2016 |
| Primary completion | 27 February 2021 |
| Estimated completion | 21 June 2021 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Level of Myeloid-Derived Suppressor Cells
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Suppression — all drugs for Suppression →
- Complication,Postoperative — all drugs for Complication,Postoperative →
- Radiotherapy — all drugs for Radiotherapy →
Sponsor
Jagiellonian University
Who can join
18 and older, any sex, with Colorectal Cancer or Suppression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to evaluate whether the preoperative level of myeloid-derived suppressor cells is associated with postoperative complications classified by Clavien-Dindo categories. Levels of all MDSC, polymorphonuclear MDSC (PMNMDSC), monocytic MDSC (MMDSC), early-stage MDSC (EMDSC) and monocytic to polymorphonuclear MDSC ratio (M/PMN MDCS) were established and compared in patients with postoperative complications, severe postoperative complications (\>= IIIA according to Clavien-Dindo) and severe septic complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04943419
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Jagiellonian University trials
Trials by the same sponsor.
- NCT07410767 — Advanced Endoscopic Resections for Rectal Neoplasms · not yet recruiting
- NCT07364864 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Duodenopancreatic Surgery by Lapar · NA · not yet recruiting
- NCT07378189 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Laparoscopic Peripheral Pancreatic · NA · not yet recruiting
- NCT07389564 — Nationwide Registry of Patients With Heart Failure With Improved and Supranormal Ejection Fraction · active not recruiting
- NCT07306689 — Posttraumatic Stress Disorder in Ectopic Pregnancy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04943419 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jagiellonian University
- Last refreshed: 7 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04943419.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing